ERBB2 and invasive breast carcinoma: In an analysis of the I-SPY2 trial in invasive breast cancer in HER2+ subsets, neoadjuvant T-DM1+P×4 followed by doxorubicin + cyclophosphamide × 4 resulted in a pCR rate of 52% (HR+, 46%; HR−, 64%) versus 22% (HR+, 17%; HR−, 33%) with taxane (paclitaxel) + trastuzumab only.